Gastrointestinal Cancers: mCRC (Issue 9) | Special Reports

Role of DPR in Colorectal Cancer

July 12, 2016

Clinical Articles

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Impact of HER2 Amplification in Colorectal Cancer

July 12, 2016

Clinical Articles

Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy

July 12, 2016

Clinical Articles

A recent retrospective analysis of the phase III 80405 trial determined that tumor location played a significant role in survival outcome differences for patients with KRAS wild-type metastatic colorectal cancer (mCRC).

SIRT Added to First-line Chemo Improves Response in Colorectal Cancer

July 11, 2016

Clinical Articles

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.